Targets › RPLP0
2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 4; Infectious disease; next expected readout May 2027.
Ribosomal protein P0 is the functional equivalent of E.coli protein L10. (UniProt, P05388)
Open in Phaseline: the race on RPLP0, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Marco Schiuma | Linezolid Bacterial 70S ribosome inhibitor | RPLP0 | Phase 4 | Linezolid | Oct 2027 |
| Global Alliance for TB Drug Development | linezolid Bacterial 70S ribosome inhibitor | RPLP0 | Phase 2 | Tuberculosis, Pulmonary | May 2027 |
Tuberculosis, Pulmonary (1) Linezolid (1)
small molecule (2)
Global Alliance for TB Drug Development (1) Marco Schiuma (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.